 |
|
|
| |
Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: Findings from a Phase 2, randomized open-label study in China
|
| |
| |
EASL 2023 June 21-24 Vienna
<
Xieer Liang1, Jinlin Hou1, Yujuan Guan2, Zhanqing Zhang3, Qing Xie4, Jidong Jia5, Jifang Sheng6, Qin Ning7, Wang Yang8, Afsaneh Mozaffarian9, Nuruddin Unchwaniwala10, Jieming Liu10, Katie Zomorodi10, Luisa M. Stamm10, Steven J. Knox10, Michele
Anderson10, Kathryn M. Kitrinos10, Grace Wang10, Yu Chen11, Junqi Niu8
1Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China; 2Guangzhou Eighth People's Hospital, Guangzhou, China; 3Fudan University, Shanghai, China; 4Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; 5Beijing Friendship Hospital, Capital Medical University, Beijing, China; 6The First Affiliated Hospital, College of Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; 7Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 8The First Hospital of Jilin University, Jilin, China; 9Former employee of Assembly Biosciences during the study; current affiliation Gilead Sciences, Foster City, CA, USA; 10Assembly Biosciences, Inc., South San Francisco, CA, USA; 11Beijing Youan Hospital, Capital Medical University, Beijing, China
|
| |
|
|
|
|
|
